Compare LSF & CCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LSF | CCEL |
|---|---|---|
| Founded | 2015 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Managed Health Care |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.3M | 29.6M |
| IPO Year | 2020 | 2022 |
| Metric | LSF | CCEL |
|---|---|---|
| Price | $3.11 | $3.52 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 35.5K | 9.5K |
| Earning Date | 05-06-2026 | 04-14-2026 |
| Dividend Yield | N/A | ★ 4.26% |
| EPS Growth | ★ 75.28 | N/A |
| EPS | N/A | ★ 0.01 |
| Revenue | ★ $49,889,286.00 | $25,384,279.00 |
| Revenue This Year | $90.82 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $359.00 |
| Revenue Growth | ★ 15.23 | 9.76 |
| 52 Week Low | $1.96 | $2.72 |
| 52 Week High | $7.94 | $5.52 |
| Indicator | LSF | CCEL |
|---|---|---|
| Relative Strength Index (RSI) | 64.13 | 48.96 |
| Support Level | $2.41 | $3.18 |
| Resistance Level | $3.60 | $3.57 |
| Average True Range (ATR) | 0.23 | 0.35 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 78.85 | 15.94 |
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
Cryo-Cell International Inc is engaged in cellular processing and cryogenic storage. The company is organized into three reportable segments namely cellular processing and cryogenic storage, with a focus on the collection and preservation of umbilical cord blood and tissue stem cells for family use and the manufacturing of PrepaCyte CB units segment, which is a processing technology used to process umbilical cord blood stem cells. The cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The company generates maximum revenue from Cellular processing and Cryogenic storage and it derives revenue from processing and testing fees and Storage segment.